Onconetix (NASDAQ: ONCO) investors back reverse stock split, adjournment

Rhea-AI Filing Summary

Onconetix, Inc. held a special meeting of stockholders on April 30, 2026, where stockholders approved a reverse stock split proposal and an adjournment proposal. Voting was based on 3,464,686 shares of common stock outstanding as of March 13, 2026, the record date.

The reverse stock split proposal received 1,301,918 votes for, 253,378 against and 1,393 abstentions. The adjournment proposal received 1,332,088 votes for, 223,071 against and 1,530 abstentions, meaning both items on the agenda were approved.

Insights

Equity structure & governance analyst

Onconetix stockholders approved a reverse split and related adjournment authority, reshaping future equity structure options.

Stockholders of Onconetix, Inc. approved a reverse stock split proposal at a special meeting held on April 30, 2026. A reverse split typically reduces the number of shares outstanding while increasing the per-share price, without changing overall shareholder value at the time of the split.

The vote (1,301,918 for, 253,378 against, 1,393 abstentions) indicates clear support among voting shares. An adjournment proposal also passed, with 1,332,088 votes for. This adjournment authority can help the company reconvene or extend the meeting process if procedural needs arise.

The filing does not detail the reverse split ratio or implementation timing in the excerpt, so actual effects will depend on future company actions and subsequent disclosures. Investors can look to later company communications and filings for the precise mechanics once the board decides to implement the split.

8-K Event Classification

2 items: 5.07, 9.01

2 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Shares outstanding record date: 3,464,686 shares Reverse split votes for: 1,301,918 votes Reverse split votes against: 253,378 votes +4 more

7 metrics

Shares outstanding record date 3,464,686 shares Common stock outstanding as of March 13, 2026

Reverse split votes for 1,301,918 votes Reverse Stock Split Proposal approval tally

Reverse split votes against 253,378 votes Reverse Stock Split Proposal opposition tally

Reverse split abstentions 1,393 votes Reverse Stock Split Proposal abstentions

Adjournment votes for 1,332,088 votes Adjournment Proposal approval tally

Adjournment votes against 223,071 votes Adjournment Proposal opposition tally

Adjournment abstentions 1,530 votes Adjournment Proposal abstentions

Key Terms

special meeting of stockholders, Reverse Stock Split Proposal, Adjournment Proposal, Emerging growth company, +1 more

5 terms

special meeting of stockholders financial

"On April 30, 2026, Onconetix, Inc. ... held a special meeting of stockholders (the “Special Meeting”)."

A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.

Reverse Stock Split Proposal financial

"1. Reverse Stock Split Proposal The votes were cast for this matter as follows"

Adjournment Proposal financial

"2. The Adjournment Proposal. The votes were cast for this matter as follows"

An adjournment proposal is a formal request made at a shareholder or board meeting to pause the meeting and reconvene at a later date or time. It matters to investors because it postpones votes and decisions, giving parties extra time to gather information, solicit support, negotiate alternatives or introduce new options — like hitting pause on a group decision to wait for more facts, which can alter outcomes and market reactions.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Common Stock, par value $0.00001 per share financial

"Title of each class ... Common Stock, par value $0.00001 per share"

Understanding 8-K Material Events →

false 0001782107 0001782107 2026-04-30 2026-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 30, 2026

Onconetix, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41294		83-2262816
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

201 E. Fifth Street, Suite 1900 Cincinnati, Ohio		45202
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (513) 620-4101

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		ONCO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 30, 2026, Onconetix, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). The matters voted on at the Special Meeting were:

(1) the approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of all of the outstanding shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to the one-year anniversary date of the special meeting, with such ratio to be determined by the Board of Directors without further approval or authorization of our stockholders, provided that the Company shall not effect reverse stock splits that, in the aggregate, exceed 1-for-100 (the “Reverse Stock Split Proposal”)

(2) the approval the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. (the “Adjournment Proposal”)

At the Special Meeting, all of the matters voted on were approved, based upon an aggregate of 3,464,686 shares of Common Stock outstanding as of March 13, 2026, the record date for the Special Meeting. The final voting results were as follows:

1. Reverse Stock Split Proposal

The votes were cast for this matter as follows:

Votes For				Votes Against				Abstentions
	1,301,918				253,378				1,393

2. The Adjournment Proposal.

The votes were cast for this matter as follows:

Votes For				Votes Against				Abstentions
	1,332,088				223,071				1,530

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K:

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Onconetix, Inc.
May 4, 2026	By:	/s/ David Allan White
	Name:	David Allan White
	Title:	Chief Executive Officer

2 

FAQ

What did Onconetix (ONCO) stockholders approve at the April 30, 2026 special meeting?

Onconetix stockholders approved a reverse stock split proposal and an adjournment proposal. These approvals give the company flexibility to implement a reverse split and to adjourn or reconvene stockholder meetings if necessary, subject to details set by the board and future disclosures.

How many Onconetix (ONCO) shares were eligible to vote at the special meeting?

Voting at the special meeting was based on 3,464,686 shares of Onconetix common stock outstanding as of March 13, 2026. This record-date share count determined which stockholders were entitled to vote on the reverse stock split and adjournment proposals presented.

What were the voting results for the Onconetix reverse stock split proposal?

The reverse stock split proposal received 1,301,918 votes for, 253,378 votes against and 1,393 abstentions. With substantially more votes in favor than against, the proposal passed, authorizing the company to move forward with reverse split mechanics as determined by its board.

How did Onconetix (ONCO) stockholders vote on the adjournment proposal?

The adjournment proposal received 1,332,088 votes for, 223,071 votes against and 1,530 abstentions. This approval allows Onconetix to adjourn and reconvene the special meeting if needed, providing procedural flexibility around stockholder voting on related corporate matters.

Does the Onconetix filing specify the reverse stock split ratio or timing?

The excerpted filing states that stockholders approved a reverse stock split proposal but does not specify the split ratio or implementation date. Those details are typically determined later by the board of directors and disclosed in subsequent company communications or regulatory filings.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB